** Shares of drug developer Cargo Therapeutics CRGX.O fall 77.4% to record low of $2.99
** On Wednesday, CRGX said it is stopping a mid-stage trial for cancer treatment
** Trial was stopped due to serious side effects in some patients, including a severe inflammatory condition - CRGX
** CRGX has $368.1 million in cash and expects it to last until mid-2028
** CRGX also said it is reducing its workforce by about 50%
** As of Sept. 30, 2024, co had 170 full-time employees - SEC filing
** CRGX fell 36.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))